AlloVir
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch AlloVir and buy or sell other stocks, ETFs, and their options commission-free!About ALVR
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases.
CEOAndrew Oxtoby, MBA
CEOAndrew Oxtoby, MBA
Employees6
Employees6
HeadquartersPalo Alto, California
HeadquartersPalo Alto, California
Founded
Founded
Employees6
Employees6
ALVR Key Statistics
Market cap49.45M
Market cap49.45M
Price-Earnings ratio-0.29
Price-Earnings ratio-0.29
Dividend yield—
Dividend yield—
Average volume50.39K
Average volume50.39K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$24.15
52 Week high$24.15
52 Week low$3.10
52 Week low$3.10
People also own
Based on the portfolios of people who own ALVR. This list is generated using Robinhood data, and it’s not a recommendation.